Mr. Timothy Ko reports

ENTHEON ANNOUNCES TERMINATION OF BUSINESS COMBINATION AGREEMENT WITH NUTRAVISOR

Further to the news release dated Jan. 19, 2026, the definitive business combination agreement dated Jan. 19, 2026, as amended on March 9, 2026, between Entheon Biomedical Corp. and Nutravisor Inc., pursuant to which the parties had agreed to complete a business combination involving a three-cornered amalgamation of Nutravisor with a wholly owned subsidiary of Entheon, having the effect of Entheon acquiring all of the issued and outstanding common shares and other securities of Nutravisor in exchange for securities of Entheon, and resulting in the reverse takeover of Entheon by Nutravisor, has been terminated.

As a result of the termination of the business combination agreement, the proposed transaction will not proceed, and the company will not complete the share consolidation, the name change or any other steps contemplated in connection with the proposed transaction.

In connection with the termination of the business combination agreement, Nutravisor paid to Entheon a cash termination payment in the amount of $175,000. In addition, Nutravisor has agreed to issue to Entheon such number of common shares of Nutravisor, or of the resulting issuer in connection with a go-public transaction, with an aggregate deemed value of $175,000, calculated based on a deemed issue price per settlement share equal to the greater of: (a) 50 cents per share; and (b) 80 per cent of the price per common share issued, sold or deemed issued in connection with Nutravisor's next liquidity event.

Trading in the common shares of the company is currently halted. The company will provide a further update regarding the status of trading in its common shares in due course.

About Entheon Biomedical Corp.

Entheon is a biotechnology research and development company interested in treating addiction and substance use disorders.

We seek Safe Harbor.